CHICAGO--(BUSINESS WIRE)--Xentria Inc., a biotech company focused on developing novel biologics to address unmet clinical needs, today announced that a new abstract showcasing XTMAB-16’s potential effect on sarcoidosis granuloma formation will be presented at the upcoming American Thoracic Society (ATS) 2022 International Conference being held in San Francisco, CA from May 13-18, 2022. Xentria partnered with Dr. Elliott Crouser, M.D., Professor of Pulmonology, Critical Care and Sleep Medicine at The Ohio State University, to explore the potential of XTMAB-16 to reduce granuloma formation in an in vitro human model representing the complex immune responses during sarcoidosis granuloma formation.
Data derived from sarcoidosis patients demonstrates XTMAB-16’s potential ability to suppress granuloma formation in the in vitro model in a dose-dependent fashion. These findings support further evaluation of XTMAB-16 in patients with sarcoidosis.
“We are excited to share important preclinical data and new developments highlighting XTMAB-16’s potential ability to reduce sarcoidosis granuloma formation for the first time,” said Thomas Shea, President of Xentria. “The data that will be presented at ATS demonstrates our focus on making a difference for people living with sarcoidosis through the development of new treatment options. We look forward to sharing this data with the scientific community and continuing to work alongside the FDA to advance clinical studies of XTMAB-16, as we further our mission of delivering breakthrough treatments for people with rare diseases.”
ATS 2022 International Conference
Poster Session:
Title: XTMAB-16 Attenuates Granuloma Formation in a Human In Vitro Sarcoidosis Model
Abstract: 5585
Session: Inflammatory Modulation in Sarcoidosis, Lung Transplant, and Other Diseases
Poster available: Tuesday May 17, 2022, 9:30 AM - 3:45 PM
More information and access to the event will be available to all registered conference participants.
Additional details on Xentria-sponsored abstracts will be available on www.xentria.com/news, starting on May 17th.
About Sarcoidosis
Sarcoidosis is a chronic, multisystem inflammatory disorder of unknown etiology that is characterized by the presence of noncaseating epithelioid granulomas, accompanied by infiltration of mononuclear cells and destruction of microarchitecture. The disease can affect the skin, eyes, heart, and central nervous system, and >90% of cases involve the lungs. Symptoms range from asymptomatic to severe—including respiratory insufficiency, blindness, neurological disease, and cardiac death. While medications for systemic organ involvement often control this disease, some patients fail to respond to initial treatments and require additional targeted therapy, resulting in significant costs and treatment burdens. This disease presents a significant unmet medical need and a very important area of research and development for Xentria.
About XTMAB-16
XTMAB-16 is a chimeric human-murine IgG1 anti-TNF monoclonal antibody being developed as a novel biologic product for the treatment of sarcoidosis. No TNF- inhibitor is currently approved for the treatment of sarcoidosis.
About Xentria
Xentria, whose name stems from the word “centrality” was founded in 2020 and is an innovative biopharmaceutics company whose primary focus is to build an expansive product pipeline of cost-effective and efficacious biologics to address critical unmet need for patients suffering from rare diseases, immunologic, metabolic, and musculoskeletal disorders, as well as oncology. Headquartered in Chicago, with partners in Israel and China, the company is dedicated to research and development, clinical science, manufacturing, and commercialization and driven to treat the clinical and social burdens of diseases while fostering sustainable growth.
To learn more about Xentria visit www.xentria.com.
